After-Hours Movers: Spectrum Pharm Sinks on Negative FDA Panel, Costco Dips on EPS
Get Alerts SPPI Hot Sheet
Join SI Premium – FREE
After-Hours Stock Movers:
Spectrum Pharmaceuticals (Nasdaq: SPPI) 28% LOWER; The FDA's Oncologic Drugs Advisory Committee (ODAC) met to review poziotinib for the treatment of patients with previously treated locally advanced or metastatic non-small cell lung cancer (NSCLC) harboring HER2 exon 20 insertion mutations. The committee voted 9-4 that the current benefits of poziotinib did not outweigh its risks.
Avenue Therapeutics, Inc. (Nasdaq: ATXI) 24% HIGHER; announced that it will effect a 1-for-15 reverse split of its common stock.
Cano Health, Inc. (NYSE: CANO) 5% HIGHER; adds to 32% intra-day gains on reports it is for sale with multiple bidders.
Calamp Corp. (NASDAQ: CAMP) 4% HIGHER; reported Q2 EPS of ($0.02), $0.01 better than the analyst estimate of ($0.03). Revenue for the quarter came in at $72.8 million versus the consensus estimate of $69.27 million.
Costco (NASDAQ: COST) 3% LOWER; reported Q4 EPS of $4.20, $0.05 better than the analyst estimate of $4.15. Revenue for the quarter came in at $72.09 billion versus the consensus estimate of $71.64 billion.
Guidewire (NYSE: GWRE) 3% HIGHER; announced that its board of directors approved a share repurchase program with authorization to purchase up to $400.0 million of its outstanding shares of Common Stock, effective immediately.
Trevi Therapeutics, Inc. (Nasdaq: TRVI) 2% LOWER; commenced an underwritten public offering of shares of its common stock.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- After-hours movers: ANSYS, National CineMedia, and more
- Midday movers: Google, Pepsi rise; Boeing, Zillow fall
- Johnson & Johnson (JNJ): FDA Advisers Unanimously Vote that carvykti Benefits Outweighing Risks as Earlier Treatment for a Type of Blood Cancer
Create E-mail Alert Related Categories
Special ReportsRelated Entities
After-Hours Movers, AdCom, FDASign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!